Anika Therapeutics resumes distribution of cartilage regeneration treatments

Written by Shayna Korol | December 05, 2018 | Print  |

Anika Therapeutics resumed distribution of its solid hyaluronic acid-based treatments after a voluntary, non-safety related recall in the second quarter.

Here are four things to know:

1. The regenerative medicine company resumed global distribution of Hyalofast, Hyalograft-C and Hyalomatrix.

2. Hyalofast is a biodegradable HA-based scaffold for hyaline-like cartilage regeneration to treat cartilage defects and injuries.

3. Following recent regulatory approvals in Thailand, the United Arab Emirates and Colombia, Hyalofast is now used in 15 countries.

4. Anika Therapeutics develops, manufactures and commercializes more than 20 products based on its proprietary HA technology.

More articles on biologics:
AlloSource earns laser etching patent: 3 notes
4 things to know about Bio2 Technologies
Spine biologics market to reach $2.72B by 2025 — 3 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months